Learn how biomarker testing guides second-line choices after CDK4/6 therapy in HR+ HER2- metastatic breast cancer, including PI3K/AKT/mTOR options.
Navigating Second-Line HR+/HER2- Metastatic Breast Cancer: Focus on PAM (PI3K/AKT/mTOR) Pathway Inhibition
Learn how liquid and tissue biopsies uncover ESR1 and PI3K mutations to personalize metastatic breast cancer second-line therapy choices.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Ropeginterferon Alfa for Essential Thrombocytopenia
2
ASCO Issues First Living Guideline for Recurrent Ovarian Cancer Treatment
3
Botensilimab/Balstilimab Elicits Major Pathologic Responses in Colon Cancer
4
ADI-212 Receives FDA IND Clearance for Castration-Resistant Prostate Cancer
5